CB-5083

DRUG2 trials

Sponsors

Cleave Biosciences, Inc.

Conditions

Advanced Solid TumorsLymphoid Hematological MalignanciesRelapsed and Refractory Multiple Myeloma

Phase 1

A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

TerminatedNCT02223598

Cleave Biosciences, Inc.Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma

Start: 2014-08-25End: 2017-07-26Target: 120Updated: 2018-02-27

A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors

TerminatedNCT02243917

Cleave Biosciences, Inc.Advanced Solid Tumors

Start: 2014-10-11End: 2017-08-25Updated: 2018-02-27